Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is twofold:
1. Assess the clinical efficacy of DBS on epilepsy according to their number and severity
at 1 year follow up.
2. Perform a cost-effectiveness analysis from the perspective of Medicare at 1 and 2 years.
The study hypothesis is that thalamic DBS (neurostimulation of the anterior nucleus of the
thalamus) will decrease significantly, the frequency (potentially 50% reduction in severe
crises) of the most severe seizures, in at least 50% of patients who have drug-resistant
partial epilepsy; and should also improve significantly the quality of life through a gain of
independence in activities of daily life, the possible recovery of functional abilities,
recovery of social or professional activities.